Clinical trials: Endocrine Disorder
Cervix Cancer, Endometrium Cancer
Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.
The protocol aims at demonstrating the technical feasibility and safety of doing endomicroscopic imaging (both probe-based confocal laser endomicroscopy (pCLE) and needle-based confocal laser endomicroscopy, nCLE) during…
- Conditions
- Cervix Cancer, Endometrium Cancer, Ovarian Cancer, Carcinoma in Situ of Fallopian Tube
- Trial name
- NCT02221076
- Testing
- Confocal Laser Endomicroscopy (CLE)
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Mauna Kea Technologies
Diabetes, Diabetes Mellitus, Type 1
Paediatric Subjects - Special Survey
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using insulin aspart in children with diabetes under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01538576
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia
This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).
- Trial name
- HCH (NCT06410976)
- Where
- 25 sites in United States, Australia and 8 more
- Volunteers
- 150 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Diabetes, Diabetes Mellitus, Type 2
Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.
- Trial name
- Lead-Ph (NCT01345734)
- Testing
- liraglutide
- Where
- Philippines
- Volunteers
- 1,056 people
- Sponsor
- Novo Nordisk A/S
Euvolemic Hyponatremia
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia
The purpose of this study is to evaluate the safety and tolerability of oral lixivaptan capsules in subjects with Euvolemic Hyponatremia.
- Trial name
- NCT00876798
- Testing
- Lixivaptan
- Where
- 90 sites in United States, Belgium and 6 more
- Volunteers
- 206 people
- Sponsor
- CardioKine Inc.
Diabetes Mellitus, Type 2
T2 FSL2 Weight Loss
To compare the impact of the FreeStyle Libre (FSL) 2 Flash Glucose Monitoring System to the current Diabetes Monitoring standard of care (SOC) on weight reduction in subjects with type 2 diabetes.
- Trial name
- NCT05168306
- Testing
- FreeStyle Libre 2 Flash Glucose Monitoring System
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Abbott Diabetes Care
Diabetic Foot Ulcers
Safety Evaluation of the KLOX BioPhotonic System in Diabetic Foot Ulcers
The primary objective of these case series is to evaluate the safety and tolerability of the KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with diabetic foot ulcers.
- Trial name
- NCT02222506
- Testing
- KLOX BioPhotonic System
- Where
- 3 sites in Canada
- Volunteers
- 10 people
- Sponsor
- KLOX Technologies Inc.
Diabetes Mellitus
G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator
Comparison of G5® Mobile Continuous Glucose Monitoring System Accuracy When Using an Automated Applicator vs. a Manual Sensor Applicator
- Trial name
- NCT02696252
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- DexCom, Inc.
Diabetes
Distinguishing Patient Groups Using Autonomic Dysfunction
A study population with impaired fasting glucose levels, impaired glucose tolerance levels and diabetes (with or without complications) along with healthy patients will be chosen as participants.
- Trial name
- NCT04964921
- Testing
- Device: ANSiScope Plus
- Volunteers
- healthy volunteers welcome
- Sponsor
- DyAnsys, Inc.
Pancreatic Ductal Adenocarcinoma
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination…
- Trial name
- NCT07076121
- Testing
- Navlimetostat, Gemcitabine, Nab-paclitaxel
- Where
- 269 sites in United States, Argentina and 34 more
- Volunteers
- 470 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer, Renal Cancer
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
The primary objectives of this Phase 1b/2 study were as follows: Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or…
- Conditions
- Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT00531284
- Testing
- Carfilzomib, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Amgen
Type 2 Diabetes
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is designed to demonstrate the long-term safety of vildagliptin in patients with type 2 diabetes. This study will study vildagliptin as add-on therapy with metformin, thiazolidinedione, α-glucosidase inhibitor (α-GI)…
- Trial name
- NCT01159249
- Testing
- Vildagliptin
- Where
- 24 sites in Japan
- Volunteers
- 245 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Effect of BKR-013 on Average Daily Glucose Levels
The purpose of this study is to evaluate the effect of BKR-013 on average daily glucose (ADG) levels in type 2 diabetes (T2D) subjects during 28 days of either placebo or active test product administration.
- Trial name
- NCT03382015
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- BioKier Inc.
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Type 2 Diabetes Mellitus
An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
This is an observational study to compare the effectiveness of dual therapy of Type II diabetes mellitus with metformin + sitagliptin versus metformin + a sulfonylurea in routine clinical practice in France.
- Trial name
- NCT01357135
- Testing
- Metformin, Sitagliptin, Sulfonylurea
- Volunteers
- 3,453 people
- Sponsor
- Merck Sharp & Dohme LLC
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ I Japan (NCT02607306)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 76 sites in Japan
- Volunteers
- 819 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus
The goal of this mechanistic study is to investigate the effect of Linagliptin in comparison to Glimepiride as add on therapy on several parameters characterizing postprandial metabolism and oxidative stress in type 2 diabetic…
- Trial name
- NCT01547104
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Marcus Borchert
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.